Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 with Cetuximab and Cisplatin in Head & Neck Cancer
NCT01009346Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in head and neck squamous cell carcinoma (HNSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 months. Started Oct 2009; status: terminated.
02
Drugs
everolimus
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01009346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01009346.